March 22 - 23, 2024
Grand Hyatt San Francisco
San Francisco, CA
Course# MPD24006
Department: Pediatrics/Center for Cancer, Blood Disorders and Cellular Therapy
Registration Fees
Physicians $550.00
Advanced Practice Professionals $400.00
Residents/Fellows $400.00
Cancellation Policy
Cancellations received in writing before March 7, 2024 will be refunded, less a $100 administrative fee. No refunds will be made on cancellations received after that date.
Please email your requests to [email protected]
Overview
SAVE THE DATE
Mark your calendar to join your colleagues at the Pediatric Precision Cancer Medicine Summit.
Grand Hyatt San Francisco
San Francisco - March 22-23, 2024
The summit brings together leading experts to discuss the latest breakthroughs in precision medicine and how these advances are changing the landscape of pediatric cancer care, research and precision-based oncology.
CME credits will be available.
More details to come, check back soon. Course outline can be viewed below.
Target audience: Physicians, Nurse Practitioners, Physician Assistants, Nurses, Clinical Geneticists, PhD Researchers, Laboratory Professionals
Objectives
- Articulate the significance of recent advances in liquid biopsies, demonstrating their application in measuring minimal residual disease and early detection of relapse.
- Investigate and appraise new therapeutic opportunities for patients in the relapsed setting using next-generation sequencing panels, while critically assessing the limitations of this technology.
- Analyze and differentiate the frequency and diversity of germline alterations relevant to cancer diagnosis in children and young adults.
- Apply knowledge of germline alterations to implement precise screening practices for patients with cancer and their families.
- Evaluate and address current barriers impeding the widespread use of immunotherapy in pediatric cancer.
- Recognize and assess the emerging importance of CART and other cell therapies in pediatric cancer.
Accreditation
In support of improving patient care, the University of California, San Francisco is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Course Outline
| Friday, March 22, 2024 | ||
| 7:00 AM | Registration and Breakfast | |
| 7:45 | Welcome and Overview | Alejandro Sweet-Cordero, MD UCSF Benioff Children’s Hospitals |
| John Maris, MD Children’s Hospital of Philadelphia |
||
| Session A: Next Generation Diagnostics | ||
| 8:00 | Cancer Gene Panel Testing in Pediatric Populations: The UCSF Experience | Jessica Van Ziffle, PhD, FACMG UCSF |
| 8:30 | Liquid Biopsy for Neuroblastoma | Lea Surrey, MD Children’s Hospital of Philadelphia |
| 9:00 | Towards Mapping Drug Resistance Heritability in Pediatric ALL | Charles Gawad, MD, PhD Stanford University |
| 9:30 | Coffee Break | |
| 9:45 | Integrated Analysis of Methylation and Transcription in Pediatric AML | Benjamin Huang, MD UCSF Benioff Children’s Hospitals |
| 10:15 | Advances in the Molecular Pathogenesis of Pediatric Brain Tumors | David Solomon, MD, PhD UCSF |
| Session B: Clinical Trials | ||
| 10:45 | Leveraging International Collaborations to Improve Outcomes in JMML | Elliot Stieglitz, MD UCSF Benioff Children’s Hospitals |
| 11:15 | Precision Medicine for Rare Pediatric Cancers: Lessons Learned and Future Directions | Ted Laetsch, MD Children's Hospital of Philadelphia |
| 11:45 | LUNCH | |
| 1:00 | An International, Multi-disciplinary, and Multi-faceted Approach to Advancing Precision-based Care for Pediatric CNS Tumors | Cassie Kline, MD, MAS Children's Hospital of Philadelphia |
| 1:30 PM | Multi-pronged Precision Approaches to Target the ALK Oncoprotein. | Yael Mossé, MD Children's Hospital of Philadelphia |
| 2:00 | Biopharma Approaches to Targeted Drug Therapy Development in Pediatric Oncology | Mark Kieran, MD, PhD Day One Bio |
| 2:30 | Coffee Break | |
| Session C: Non-Catalytic Oncogenic Targeting | ||
| 2:45 | Targeting Oncogenic N-myc Complexes in High-risk Pediatric Neural Tumors | Bo Qiu, MD, PhD UCSF Benioff Children’s Hospitals |
| 3:15 | Targeting Translational Control of PAX3-FOXO1 | Amit J. Sabnis, MD UCSF Benioff Children’s Hospitals |
| 3:45 | Targeted Protein Degradation of Pediatric Oncoproteins: Strategies and Progress | Gwenn Hansen, PhD Nurix |
| 4:15 | Coffee Break | |
| 4:30 | Understanding the Pathogenesis and Developing Therapeutics for Fibrolamellar Carcinoma | Sanford M. Simon, PhD Rockefeller University; The Fibrolamellar Registry |
| 5:00 | Targeting Intracellular Proteins through MHC 1 for Cancer Applications | Charles Craik, MD UCSF |
| 5:30 | Pax3:Foxo1 Targeting Genetically and Via Multiple Pharmacological Approaches for Clinical Investigation | Charles Keller, MD Children's Cancer Therapy Development Institute |
| 6:00 PM | Adjourn | |
| Saturday, March 23, 2023 | ||
| 7:00 AM | Breakfast | |
| Session D: Cancer Predisposition | ||
| 8:00 | Replication Repair Deficiency in Brain Tumors: Linking Causes with Therapy | Uri Tabori, MD The Hospital for Sick Children |
| 8:30 | COG ACNS0333: Lessons Learned from the First Cooperative Group ATRT Trial | Alyssa T. Reddy, MD UCSF Benioff Children's Hospital |
| 9:00 | The Diagnosis and Long-term Care of Children with a Hereditary Predisposition to Cancer. | Nicola Cadenas, MD UCSF Benioff Children’s Hospitals |
| 9:30 | Coffee Break | |
| 9:45 | Unraveling the Genetic Basis of Neuroblastoma: Recent Findings, Future Directions, and Translational Opportunities | Sharon Diskin, PhD Children's Hospital of Philadelphia |
| 10:15 | Risk Stratification to Personalize Therapy for Neurofibromatosis Type 1-Associated Tumors | Chelsea Kotch, MD MSCE Children’s Hospital of Philadelphia |
| 10:45 | Coffee Break | |
| Session E: Immunotherapies | ||
| 11:00 | Novel Strategies of Targeting Tumor Antigens In Adult and Pediatric Glioma | Hideho Okada, MD, PhD UCSF |
| 11:30 | Proteomic Strategies to Uncover Cellular Therapy Targets for Refractory Pediatric Hematologic Malignancies | Arun Wiita, MD UCSF |
| 12:00 PM | Developing GPC2-directed Immunotherapies for Pediatric Cancers | Kristopher Bosse, MD Children's Hospital of Philadelphia |
| 12:30 | LUNCH | |
| 1:45 | CAR T Cell Therapy for CNS Malignancies | Jessica Foster, MD Children’s Hospital of Philadelphia |
| 2:15 | Leveraging Real-world Data to Advance Immunotherapy Outcomes | Liora Schultz, MD Stanford University |
| 2:45 | Closing Remarks | Alejandro Sweet-Cordero, MD UCSF Benioff Children’s Hospitals |
| John Maris, MD Children’s Hospital of Philadelphia |
||
| 3:00 PM | Adjourn | |
Course Chairs
Alejandro Sweet-Cordero, MD
UCSF Benioff Children’s Hospitals
Professor of Pediatrics
Joey Mack
UCSF Benioff Children’s Hospitals
Service Line Director, CCBDCT
John M. Maris, MD
Children’s Hospital of Philadelphia
Giulio D'Angio Professor of Pediatric Oncology
Perelman School of Medicine at the University of Pennsylvania
UCSF Faculty
Nicola Cadenas, MD
Charles Craik, PhD
Benjamin Huang, MD
Bo Qiu, MD, PhD
Alyssa T. Reddy, MD
Amit J. Sabnis, MD
David Solomon, MD, PhD
Elliot Stieglitz, MD
Jessica Van Ziffle, PhD, FACMG
Guest Faculty
Kristopher Bosse, MD
Sharon Diskin, PhD
Jessica Foster, MD
Charles Gawad, MD, PhD
Gwenn Hansen, PhD
Charles Keller, MD
Mark Kieran, MD, PhD
Cassie Kline, MD, MAS
Chelsea Kotch, MD, MSCE
Theodore W. Laetsch, MD
Yael Mosse, MD
Hideho Okada, MD, PhD
Liora Schultz, MD
Sanford Simon, PhD
Lea Surrey, MD
Uri Tabori, MD
Arun Wiita, MD, PhD
Travel & Lodging
Grand Hyatt San Francisco
345 Stockton Street
San Francisco, CA 94108
Online Reservations Available Here
The last day to reserve the rooms at the group rate is on February 29th
UNITED AIRLINES
UCSF has negotiated special fares with United Airlines for our course attendees. Download Online Booking Instructions (.pdf)
Code ZMGE963115
Exhibitors
Exhibit Fee: $TBA
Email Contact for Exhibits [email protected]
Exhibit Description
Exhibitors receive the following benefits:
- (1) 6’ x 30” tabletop exhibit space at UCSF assigned location in exhibit hall
- Standard acknowledgement from the podium
- Acknowledgement in the course syllabus distributed to each registrant*
- (2) complimentary exhibitor attendees and (1) copy of the course syllabus
Exhibit Hours
(subject to updating)
EXHIBIT HOURS (subject to updating)
| March 22, 2024 | |
| 7:00- 8:00AM | Exhibit Area open during Registration |
| 9:30- 10:30AM | Coffee Break in Exhibit Area |
| 3:00- 3:30PM | Coffee Break in Exhibit Area |
| March 23, 2024 | |
| 7:00- 8:00AM | Continental Breakfast in Exhibit Area |
| 9:30- 10:30AM | Coffee Break in Exhibit Area |
| 3:00- 3:30PM | Coffee Break in Exhibit Area |